October 2015

New Product - Abstral

Abstral (fentanyl citrate) is a potent mu-opioid analgesic with rapid onset of analgesia and short duration of action. It is indicated for the management of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic pain. Abstral is contraindicated in nonopioid tolerant patients because of the risk of life threatening respiratory depression; severe respiratory depression or severe obstructive lung conditions; and use in patients not receiving opioid maintenance therapy for cancer related pain. Abstral is available as 100 microgram, 200 microgram, 300 microgram, 400 microgram, 600 microgram and 800 microgram sublingual tablets in packs of 10’s and 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au